Showing results (181-190 of 187) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 187 results.
American Journal of Hematology|December 10, 2019
Second cancers in MPN: Survival analysis from an international studyMonia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
Annals of Hematology|March 4, 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment optionsJean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, et al.
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Blood|March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMTNicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
Hematological Oncology|March 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)Paola Guglielmelli, Massimo Breccia, Francesco Mendicino, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
Pageof 19